Clinical Outcome Following Endovascular Therapy for Femoropopliteal Lesion With TASCII Class A and B

The aim of this study was to investigate the outcome following endovascular therapy(EVT) for femoropopliteal(FP) lesion classified into TransAtlantic Inter-Society Consensus (TASC) II class A and B. This study was a multicenter retrospective analysis. A total of 2742 consecutive patients (3471limbs) with FP disease and 2003 limbs with TASCII class A and B lesions were analyzed in current study; 1169 (58.4%) were stenting, 834 (41.6%) were plain old balloon angioplasty (POBA) alone. The mean follow-up term were 4.6 ± 0.1 years. The mean reference vessel diameter (RVD) was 58.7 ± 33.8 mm and the mean lesion length was 5.2 ± 1.0 mm. Primary patency was significantly higher in the stent group (85.3%, 69.6% and 59.9% at 1, 3 and 5 years) than that in the POBA group (76.2%, 59.6% and 49.3% at 1, 3 and 5 years; P < .0001). Assisted primary patency was also better in the stent group than that in the POBA group (P = .0002) and the difference in secondary patency between in the two groups was similarly significant (P = .006). Limited to lesions with RVD below 4.5 mm, there was no difference in primary patency between in the two groups (stent vs POBA; 73.0% vs 74.8%, 57.2% vs 53.2% and 46.8% vs 45.4% at 1, 3 and 5 years; P = .67). Diabetes, hemodialysis, the history of cerebrovascular disease, absence of cilostazol, POBA alone and RVD <4.5 mm were found to be independent predictors of primary patency. FP stenting improves the primary, assisted-primary and secondary patency for the femoropopliteal TASCII class A and B lesions.